Coherus Oncology (CHRS) highlighted its commercial and clinical strategy at the 2026 Global Healthcare Conference, projecting its lead immunotherapy LOQTORZI could reach $175 million in annualized sales by 2026—a milestone that would cover direct costs and fund pipeline expansion. CEO Denny Lanfear emphasized the company’s focus on nasopharyngeal cancer, where LOQTORZI is the sole FDA-approved first-line treatment with chemotherapy, achieving a six-year survival benefit of nearly twice that of chemotherapy alone.
The drug’s success has positioned Coherus as a commercial-stage oncology player, with $15 million in projected quarterly sales for LOQTORZI in 2026, sufficient to cover manufacturing, royalties and operational expenses. By late 2027, the company expects quarterly revenues of $30 million to $35 million, a threshold Lanfear described as critical for accelerating pipeline development and sustaining corporate operations. Beyond LOQTORZI, Coherus is advancing two other CCR8-targeting antibodies—Tagmokitug and Casdozokitug—each with distinct clinical profiles and partnerships.
Tagmokitug, a CCR8-targeting antibody, has completed enrollment in a 40-patient head and neck cancer study with toripalimab, showing durable responses in HPV-positive and high TIRI-score patients. The drug is also advancing in gastrointestinal cancers, prostate cancer (a collaboration with Johnson & Johnson’s pasritamig) and colorectal cancer. With no off-target binding and picomolar affinity, Tagmokitug’s safety profile includes reversible liver enzyme elevations. Data from these studies are expected by October 2025 and fall 2025, respectively.
Casdozokitug, a first-in-class IL-27 antagonist, demonstrated a 38% overall response rate in hepatocellular carcinoma when combined with atezolizumab and bevacizumab, outperforming the IMbrave150 control arm. A 72-patient randomized trial (U.S. and Asia-Pacific) is nearing completion, with interim data due by the end of 2025.
Coherus operates in a competitive oncology landscape, with rivals including Bristol Myers Squibb, Amgen and Johnson & Johnson. While competitors have similar pipelines, Lanfear argued Coherus’s molecules offer selectivity advantages, particularly in targeting CCR8, a receptor expressed on tumor-infiltrating regulatory cells. The company’s total addressable market for nasopharyngeal cancer is estimated at $250 million, with Wall Street analysts citing a $4 to $10 per share price target for CHRS stock.
The company’s financial trajectory hinges on LOQTORZI’s commercialization and pipeline milestones. With $15 million in annualized sales by 2026, Coherus aims to transition from clinical development to sustained growth, leveraging its lead position in targeted immunotherapy.
Key dates include October 2025 for Tagmokitug’s head and neck study data, fall 2025 for the prostate cancer collaboration, and end-2025 for Casdozokitug’s liver cancer results. By late 2027, Coherus expects to achieve $30 million–$35 million in quarterly revenues, a threshold that will enable further investment in its pipeline and operational scaling.
The company’s strategy reflects a balance between commercial success and innovation, positioning LOQTORZI as a cornerstone of its growth while advancing next-generation therapies through targeted partnerships and rigorous clinical development.
